AVADEL PHARMACEUTICALS PLC
DelistedCIK 1012477fmd_1WWQS20DD526QC4Q7EC7YX14QYManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2025, 60 periods
Latest annual · FY2024
Millions- Total revenues
- 169
- Gross profit
- 154
- Operating income
- (42)
- Net income
- (49)
- Free cash flow
- (47)
Latest quarter · Q3 FY2025
Millions- Total revenues
- 77
- Gross profit
- 82
- Operating income
- 2
- Net income
- 0
- Free cash flow
- 22
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2021 to FY2024
- n/m
- Revenue, 5 yearsFY2019 to FY2024
- +23.4%
- Net income, 5 yearsFY2019 to FY2024
- n/m
AVADEL PHARMACEUTICALS PLC financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Revenue | $169.1 million | $28 million | +504.8% | 10-K 2025-03-03 · proof |
| Gross profit | $153.8 million | $27.1 million | +467.3% | 10-K 2025-03-03 · proof |
| Operating income | -$42.4 million | -$137.8 million | 10-K 2025-03-03 · proof | |
| Net income | -$48.8 million | -$160.3 million | 10-K 2025-03-03 · proof | |
| Cash from operating activities | -$46.9 million | -$128.5 million | 10-K 2025-03-03 · proof | |
| Free cash flow | -$46.9 million | -$128.5 million | 10-K 2025-03-03 · proof | |
| Total assets | $164.2 million | $164.7 million | -0.3% | 10-K 2025-03-03 · proof |
| Total liabilities | $90.4 million | $77 million | +17.4% | 10-K 2025-03-03 · proof |
| Cash and cash equivalents | $51.4 million | $31.2 million | +64.8% | 10-K 2025-03-03 · proof |
- What was AVADEL PHARMACEUTICALS PLC's revenue in fiscal 2024?
- AVADEL PHARMACEUTICALS PLC reported revenue of $169.1 million for fiscal 2024 (the year ended Dec 31, 2024), against $28 million the year before (+504.8%). Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What was AVADEL PHARMACEUTICALS PLC's gross profit in fiscal 2024?
- AVADEL PHARMACEUTICALS PLC reported gross profit of $153.8 million for fiscal 2024 (the year ended Dec 31, 2024), against $27.1 million the year before (+467.3%). Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What was AVADEL PHARMACEUTICALS PLC's operating income in fiscal 2024?
- AVADEL PHARMACEUTICALS PLC reported operating income of -$42.4 million for fiscal 2024 (the year ended Dec 31, 2024), against -$137.8 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What was AVADEL PHARMACEUTICALS PLC's net income in fiscal 2024?
- AVADEL PHARMACEUTICALS PLC reported net income of -$48.8 million for fiscal 2024 (the year ended Dec 31, 2024), against -$160.3 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What was AVADEL PHARMACEUTICALS PLC's cash from operating activities in fiscal 2024?
- AVADEL PHARMACEUTICALS PLC reported cash from operating activities of -$46.9 million for fiscal 2024 (the year ended Dec 31, 2024), against -$128.5 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What was AVADEL PHARMACEUTICALS PLC's free cash flow in fiscal 2024?
- AVADEL PHARMACEUTICALS PLC reported free cash flow of -$46.9 million for fiscal 2024 (the year ended Dec 31, 2024), against -$128.5 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What are AVADEL PHARMACEUTICALS PLC's total assets?
- As of Dec 31, 2024, AVADEL PHARMACEUTICALS PLC reported total assets of $164.2 million, against $164.7 million a year earlier (-0.3%). Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What are AVADEL PHARMACEUTICALS PLC's total liabilities?
- As of Dec 31, 2024, AVADEL PHARMACEUTICALS PLC reported total liabilities of $90.4 million, against $77 million a year earlier (+17.4%). Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
- What are AVADEL PHARMACEUTICALS PLC's cash and cash equivalents?
- As of Dec 31, 2024, AVADEL PHARMACEUTICALS PLC reported cash and cash equivalents of $51.4 million, against $31.2 million a year earlier (+64.8%). Source: the 10-K filed with the SEC on Mar 3, 2025. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1012477&period_type=annual&limit=5"Information only, not investment advice.